Quantitative relationship between cycle threshold values and infectious influenza virus in patient nasopharyngeal samples Authors: Kain S Saygan, Jeroen J A van Kampen, Daphne G J C Mulders, Theo Bestebroer, Dennis de Meulder, Richard Molenkamp, Mirle van Geest, Ron A M Fouchier, Sander Herfst, Pieter L A Fraaij Published: 2026 ABSTRACT AbstractReal-time reverse transcription polymerase chain reaction (rRT-PCR) is nowadays commonly used to diagnose viral infections. This assay provides cycle threshold (Ct) values, which inversely correlate with viral load but do not directly indicate infectivity. The relationship between Ct values and infectivity remains unclear. As a first step, we assessed this relationship in nasopharyngeal samples from 97 seasonal influenza A (IAV) and 95 influenza B (IBV) virus-rRT-PCR-positive patients. Samples were cultured, viral RNA was quantified using reverse transcriptase digital PCR, and antibody titers against hemagglutinin (HA) were evaluated. We found a robust inverse correlation between sample Ct value and infectious virus titer and virus cultures are consistently positive at Ct < 22 with a 10% positive culture probability near Ct 36, which corresponds to 5.37 × 102 and 1.57 × 103 RNA copies mL−1 for seasonal IAV and IBV, respectively. Nearly all available serum samples showed HA-specific antibodies, with no correlation between HA titer and Ct value or virus titer. In conclusion, these results support the use of Ct values as a semiquantitative proxy for infectious viral load and underscore their value in interpreting molecular diagnostics and informing infection prevention and control strategies.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-54249-x.Subject terms: Diseases, Immunology, Medical research, Microbiology Introduction Real-time reverse transcription polymerase chain reaction (rRT-PCR) is widely regarded as a gold standard for the detection of respiratory viruses in clinical and environmental samples1–5. This assay yields a cycle threshold (Ct) value, which serves as a semi-quantitative indicator of the presence of viral genetic material present in a sample. Notably, these Ct values are inversely proportional to the amount of target nucleic acid; lower Ct values mean higher concentrations of viral RNA or DNA, and vice versa. However, it is critical to recognize that the mere detection of viral genetic material does not necessarily indicate the presence of infectious virus. Despite this limitation, Ct values are occasionally used as a proxy for infectivity6,7. The prevailing assumption is that low Ct values reflect the presence of infectious virus, whereas high Ct values suggest its absence. For certain viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this correlation has been substantiated through experimental studies8,9. However, no such correlation has been definitively established for seasonal influenza A virus (IAV) or influenza B virus (IBV). Understanding the correlation between Ct values and the presence of infectious virus is not only important for advancing virological research but also for informing infection prevention and control (IPC) strategies. For example, understanding this correlation would improve the selection of clinical samples for virus culture in laboratory settings as well as the interpretation of data from airborne transmission research, which now often relies on the presence of viral RNA instead of infectious virus. More importantly, a clear understanding of this relationship could significantly enhance IPC protocols by enabling the use of Ct values, most likely in combination with patient characteristics, in future protocols to inform IPC decision-making, such as the initiation or discontinuation of antiviral therapies or the implementation of patient isolation measures. As an initial step towards addressing this knowledge gap, the present study investigates the correlation between Ct values and the presence and quantity of infectious seasonal IAV or IBV in patient nasopharyngeal (NP) samples. This work aims to provide foundational data that may support more informed and effective use of rRT-PCR results in both clinical, IPC, and research contexts. Methods Definitions For the purpose of this study, “infectious virus” refers to virus present in clinical samples that was capable of initiating an infection and replication in cell cultures, as demonstrated by cytopathic effects or agglutination activity within 3 to 6 days post-inoculation. Patient NP sample selection Ninety-seven seasonal IAV- and 95 IBV-positive patient NP swab samples with varying Ct values were obtained from the BioBank of the diagnostics unit of the Viroscience department of Erasmus Medical Center. These samples were originally collected in UTM® Universal Transport Medium™ 3C057N (Copan, Italy) for routine clinical care. Automated RNA isolation and rRT-PCR analysis were then performed by the validated10 and CE-IVD approved Panther Fusion System (Hologic, USA) to determine sample Ct values. Patient samples analyzed before 29 September 2023 were tested using the Panther Fusion® Flu A/B/RSV assay (Hologic) whereas samples analyzed from 29 September 2023 onward were tested using the Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay (Hologic), which uses identical IAV, IBV, and respiratory syncytial virus primer-probe sets with the addition of SARS-CoV-2 specific targets. Prior to inclusion in this study, samples were anonymized. Seasonal IAV samples were randomly selected from samples obtained between 2020 and 2023. This timeframe was extended to between 2018 and 2023 for IBV due to limited IBV circulation between 2020 and 2023. Samples were included only if sufficient material remained for other research or diagnostic purposes after allocation, and if donors had not registered in the local opt-out registry. Cell culture and virus stocks Madin-Darby Canine Kidney (MDCK) cells (ATCC-CRL-2935) and humanized MDCK (hCK) cells11 were cultured at 37 °C and 5% CO2. Culture medium for both cell lines consisted of Minimum Essential Media (MEM) with Earle’s balanced salt solution (BSS) (Capricorn Scientific GmbH, Germany) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, USA), 100 IU mL−1 penicillin (PEN, Capricorn Scientific), 100 µg mL−1 streptomycin (STR, Capricorn Scientific), 2 mM L-glutamine (L-glu, Capricorn Scientific), 10 mM N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES, Capricorn Scientific), 1.5 mg mL−1 sodium bicarbonate (NaHCO3, Gibco, USA), and 1x MEM non-essential amino acids (NEAA, Capricorn Scientific). HCK culture medium was additionally supplemented with 2 µg mL−1 puromycin (InvivoGen, USA) and 10 µg mL−1 blasticidin (InvivoGen). A/NL/602/09 (pdmH1N1) stocks were prepared by passaging on embryonated eggs and on MDCK cells. Virus titrations Endpoint titrations of (seasonal) IAV and IBV rRT-PCR-positive stock- and patient samples were conducted in hCK- and MDCK cells, respectively, as these were the most optimal cell lines for each virus. Cells were seeded in flat-bottom 96-wells plates and grown to confluency overnight at 37 °C and 5% CO2. Cells were then washed twice with infection medium (MEM with Earle’s BSS (Gibco) supplemented with 100 IU mL−1 PEN, 100 IU mL−1 STR, 2 mM L-glu, 10 mM HEPES, 1.5 mg mL−1 NaHCO3, 1x NEAA, and 0.8 µg ml−1 tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Sigma-Aldrich, USA)) and inoculated with 100 µl of patient NP sample 10-fold serially diluted in infection medium. After incubation of 1 h at 37 °C and 5% CO2, cells were washed twice and cultured in 200 µl infection medium for 3 to 6 days at 37 °C–33 °C and 5% CO2 for seasonal IAV and IBV, respectively. Infectious virus titers (tissue culture infectious dose 50%: TCID50 mL−1) were determined by cytopathic effect or agglutination activity for seasonal IAV and IBV, respectively, and calculated from ten replicates using the Spearman-Karber method12,13. Simulation of multiple freeze-thaw cycles Two seasonal IAV- and 2 IBV-positive patient NP samples were obtained from the Erasmus Medical Center BioBank. A/NL/602/09 stock samples were stored in infection medium prior to further processing. Both patient NP samples and A/NL/602/09stock samples were processed by vortex mixing, after which the volume was adjusted to 4 mL dilution medium (Dulbecco’s Modified Eagle Medium (Lonza, Switzerland) supplemented with NaHCO3 (7.5%) (Lonza), 20 mM HEPES (Lonza), 10000 U mL−1 PEN/STR (Lonza), and 0.25 mg mL−1 Amphotericin B (pharmacy-grade, sourced from Erasmus MC Hospital Pharmacy). All samples were then filtered through a 0.45 μm pore-size syringe filter. To simulate multiple freeze-thaw cycles, samples were stored at -80 °C for a minimum of 2 h, followed by thawing at room temperature. After each freeze-thaw cycle, samples were titrated as described in Sect. Virus titrations. Virus characterization and digital PCR analysis As no Panther Fusion System PCR assays are available for hemagglutinin (HA) protein subtyping, a separate PCR analysis was performed. First, viral RNA was isolated from 60 µL patient NP sample using 50 µL magnetic beads AMPure XP, Beckman Coulter) as described before14. After isolation, RNA was eluted in 50 µL bidest water and stored at -80 °C until use. Seasonal IAV subtypes and IBV sublineages in NP samples were determined by rRT-PCR. For the subtyping of seasonal IAV NP samples, 8 µL RNA elution was mixed with rRT-PCR mix containing 5 µL TaqMan™ Fast Virus 1-step master mix (ThermoFisher Scientific), 6.6 µL nuclease free water, and 0.4 µL primer/probe mix. For the IBV NP samples, 5 µL RNA elution was mixed with rRT-PCR mix containing 5 µL TaqMan™ Fast Virus 1-step master mix, 7 µL nuclease free water, and 3 µL primer/probe mix. Primers and probes are listed in Supplementary Table 1. Amplification and detection of the seasonal IAV subtypes and IBV sublineages were conducted on a LightCycler 480 (Roche, Switzerland), validated by10 using the following protocol: 5 min 50 °C, 20 s 95 °C, [3 s 95 °C, 30 s 60 °C] x 45 cycles. Reverse transcriptase digital PCR (RT-dPCR) (ThermoFisher Scientific) analysis was conducted according to the manufacturer’s protocol to determine influenza virus RNA concentrations in patient NP samples. Isolated RNA was first diluted 1:10, and 4 µL of the diluted RNA was added to the RT-dPCR reaction mix consisting of 2.5 µL Absolute Q™ 1 step RT Digital PCR Master Mix (4x) (ThermoFisher Scientific), 0.3 µL primer/probe mix, and 3.1 µL nuclease free water. Primers and probes are listed in Supplementary Table 2. RNA concentrations were quantified using the QuantStudio™ Absolute Q™ Digital PCR System (ThermoFisher Scientific) according to the following protocol: 10 min 50 °C, 10 min 96 °C, [5 s 96 °C, 15 s 60 °C] x 40 cycles. The following formula was used to calculate RNA concentrations: RNA concentrations were afterwards corrected for the dilution factor. Serological analysis Hemagglutination inhibition (HI) titers in patient sera were determined using HI assays. From 4 to 6 seasonal IAV- and IBV-rRT-PCR-positive patients, respectively, serum samples were acquired that were collected for routine clinical care and on the same day as their corresponding autologous NP sample. Virus was isolated from the autologous NP samples of these patients, and virus stocks were produced for use in HI assays. For this purpose, T25 flasks containing hCK or MDCK cells were inoculated with 50 µL seasonal IAV- or IBV-rRT-PCR-positive patient NP sample, respectively, diluted in 2 mL infection medium. The flasks were then incubated for 2 h at 37 °C and 5% CO2. After incubation, the inoculum was removed, and cells were washed twice with infection medium. Cells were cultured in 8 mL infection medium supplemented with 100 µg mL−1 Primocin (InvivoGen) for 42 h at 37 °C and 5% CO2 for seasonal IAV and 33 °C and 5% CO2 for IBV15–18. Patient sera were pre-treated with receptor-destroying enzyme (RDE), which was prepared in-house by filtering Vibrio cholerae cultures, at a 1:6 ratio and incubated overnight at 37 °C. RDE was then inactivated by incubation for 1 h at 56 °C. HI assays were performed following standard procedures18 and as described before19, starting with a 1:3 dilution of patient serum samples in PBS. Next, viruses isolated from the patient NP samples were incubated with the corresponding autologous serum samples. HI titers were then expressed as the reciprocal value of the highest dilution of serum that completely inhibited the virus’ ability to agglutinate the erythrocytes. Statistical analyses The correlation between sample Ct values and virus titers was determined using Spearman’s correlation. Continuous variables such as antibody titers, Ct values and virus titers were compared using unpaired t-tests. The relationship between Ct values and RNA concentrations was analyzed using linear regressions. Statistical analyses were conducted using Graphpad Prism (version 10.2.3). R (version 4.3.2) was used to perform the logistic regression. Results The effect of multiple freeze-thaw cycles on seasonal IAV and IBV viability As BioBank samples may also be used for additional diagnostic purposes or other projects, it is anticipated that these samples have been thawed at least once to a maximum of three times. It was therefore first determined to what extend multiple freeze-thaw cycles affect virus viability. Samples were subjected to multiple freeze-thaw cycles, and titrations were conducted after each cycle to determine virus titers. Readily available A/NL/602/09 virus stocks were used for an initial assessment of the effect of repeated freeze-thaw cycles on virus viability. Titrations of the virus stock A/NL/602/09 showed no decline in virus titers after 15 freeze-thaw cycles (Fig. 1a; Supplementary Table 3). However, given that laboratory-grown virus stocks are stored in optimal medium, the experiments were repeated with two seasonal IAV- and two IBV positive patient NP samples, as these sample types represent the primary material of interest in this study. Similar to the virus stock, titrations of the patient NP samples showed no decline in virus titers after four freeze-thaw cycles (Fig. 1b and c; Supplementary Table 4). Infectious virus titers through multiple freeze-thaw cycles for (a) A/Netherlands/602/09 virus stock, (b) seasonal IAV positive patient samples, and (c) IBV positive patient samples. Dotted horizontal line represents the limit of detection. Error bars indicate standard error. X: unknown number of previous freeze/thaw cycles, estimated to be between 1 and 3. N: number of freeze/thaw cycles in the current experiment. IAV, influenza A virus; IBV, influenza B virus; TCID50, 50% tissue culture infectious dose. Correlation between Ct value and virus titers In total, 97 seasonal IAV- and 95 IBV-rRT-PCR-positive patient NP samples were included. Infectious virus could be cultured from 69 out of 97 (71%) seasonal IAV- and 44 out of 95 (46%) IBV-positive patient NP samples. The median Ct values were 28.8 for seasonal IAV and 32.4 for IBV, with a significant difference between the two (Wilcoxon rank-sum test, W = 2857, p = 2.7 × 10− 6). Correlation analyses showed for both seasonal IAV and IBV a strong inverse correlation between sample Ct value and infectious virus titers in TCID50 mL−1 (Fig. 2a and b) (Spearman’s correlation, r = -0.83, 95% CI -0.88 to -0.75, p = < 0.0001; and r = -0.79, 95%CI -0.86 to -0.70, p = < 0.0001, respectively). The correlation between sample Ct value (as determined by the Panther Fusion System) and virus titers for (a) seasonal IAV-rRT-PCR-positive- (n = 97) and (b) IBV-rRT-PCR-positive (n = 95) patient NP samples and the distribution of the (c) seasonal IAV H1 and H3 subtypes and (d) IBV VIC and YAM sublineages (as determined by the LightCycler480) over Ct values and virus titers. Dark green and dark blue dots represent individual seasonal IAV and IBV patient airway samples, respectively, which were positive for virus culture. Red squares indicate individual seasonal IAV- and IBV-positive patient samples which were virus culture negative. Dark green squares and light green triangles represent individual samples that were of the H1 and H3 subtype, respectively. Dark blue diamonds and light blue inverted triangles represent individual samples that were of the VIC and YAM sublineage, respectively. Grey circles indicate individual samples that could not be typed due to elevated Ct values. Dotted horizontal line represents limit of detection. Correlations were determined using Spearman’s correlation. IAV, influenza A virus; IBV, influenza B virus; Ct value, cycle threshold value; TCID50, 50% tissue culture infectious dose; VIC, Victoria; YAM, Yamagata, TCID50, 50% tissue culture infectious dose. As seasonal IAV and IBV comprise different subtypes and -lineages, respectively, we evaluated whether Ct values and virus titers varied among these subtypes and -lineages. For seasonal IAV, 44 out of 97 samples were identified as subtype H1, 42 as H3, and 11 could not be subtyped due to a low RNA load (Fig. 2c). No significant differences in virus titers or Ct values were observed between the H1 and H3 subtypes (unpaired t-test; p = 0.37 and p = 0.89). For IBV, 48 out of 95 samples belonged to the Yamagata (YAM) lineage, 21 to the Victoria (VIC) lineage, and 26 were untyped due to a low RNA load (Fig. 2d). Notably, the VIC lineage exhibited significantly higher virus titers and lower Ct values compared to YAM (unpaired t-test; p < 0.0001 and p = 0.0002). The probability of a positive seasonal IAV or IBV culture per Ct value A logistic regression model was fitted to estimate the probability of obtaining a positive virus culture based on Ct values determined by rRT-PCR. For seasonal IAV, the probability of culture positivity was 100% at Ct values ≤ 23.4, declining to 50% at Ct 31.8 and 10% at Ct 36.1 (Fig. 3a). IBV showed a similar pattern, with a 100% probability at Ct ≤ 21.6, 50% at Ct 31.1, and 10% at Ct 36.2 (Fig. 3b). For both viruses, the steepest decline in culture positivity occurred within a narrow Ct range between 29 and 32. The probability of a positive (a) seasonal IAV or (b) IBV virus culture per Ct value. Black dots represent individual patient samples which were either virus culture positive (1.0) or negative (0.0). Black dotted lines highlight the 50% (0.5) and 10% (0.1) probabilities of a positive virus culture, with its corresponding Ct value. Transparent shaded grey area represents 95% confidence interval. IAV, influenza A virus; IBV, influenza B virus; Ct value, cycle threshold value. Relation between Ct values and RNA concentrations The relationship between RNA concentrations and Ct values was determined using RT-dPCR to provide standardized values. In total, 78 out of 97 seasonal IAV and 58 out of 95 IBV samples were quantifiable in this analysis. The remaining samples could not be quantified due to the low RNA concentrations. RT-dPCR analyses showed a strong relation between Ct values and RNA concentrations for both seasonal IAV- and IBV-rRT-PCR-positive NP samples (simple linear regression; slope = -0.25, 95% CI -0.28 to -0.23, R2 = 0.81, p < 0.0001, n = 78; and slope = -0.26, 95% CI -0.30 to -0.23, R2 = 0.82, p < 0.0001, n = 58, respectively) (Fig. 4a and b). Based on the probability analysis, it was extrapolated that 100% of the patient samples were culture positive at RNA concentrations > 4.96 and 5.61 Log10 RNA copies mL−1 for seasonal IAV and IBV, respectively. The lowest RNA concentrations of samples that resulted in a positive virus culture were 1290 RNA copies mL−1 for seasonal IAV and 213 RNA copies mL−1 for IBV (Fig. 4c). The correlation between Ct value and RNA concentrations (copies mL−1) for (a) seasonal IAV and (b) IBV. Light green and light blue dots represent individual patient airway samples positive for virus culture for seasonal IAV and IBV, respectively. Red circles represent individual patient airway samples negative for virus culture. Correlations were determined using simple linear regression. (c) Shows a summary of RNA concentrations per 100%, 50% and 10% probability of a positive virus culture for seasonal IAV and IBV. Ct value, cycle threshold value; IAV, influenza A virus; IBV, influenza B virus. The presence of hemagglutination-inhibiting antibodies in patient serum As antibodies against the HA protein can prevent virus binding to cells and thereby inhibit virus culture20, HI assays were performed to determine whether patients had detectable serum antibody titers against the HA protein at the time of NP sample collection. A total of four seasonal IAV and six IBV serum samples, each paired with their autologous NP sample, were included in this study. These NP samples had Ct values ranging from Ct 20 to Ct 31 for seasonal IAV, and Ct 25 to Ct 34 for IBV, respectively. In total, sera from 2 out of 4 seasonal IAV-rRT-PCR positive and 5 out of 6 IBV-rRT-PCR-positive patients had antibody titers of ≥ 40 against the homologous HA protein, which is generally regarded as protective21,22(Table 1). Separate linear regression analyses showed no correlation between Ct values and antibody titers for seasonal IAV and IBV (slope = -0.0027, 95% CI -0.0072 to 0.0017, R2 = 0.773, p = 0.12, n = 4, and slope = -0.0016, 95% CI -0.0048 to 0.0016, R2 = 0.31, p = 0.25, n = 6, respectively) (Supplementary Fig. 1a & 1b). Likewise, no correlation was found between TCID50 titers and antibody titers for seasonal IAV and IBV (slope = 0.0190, 95% CI -0.0277 to 0.0657, R2 = 0.61, p = 0.22, n = 4, and slope = 0.0017, 95% GI -0.0154 to 0.0121, R2 = 0.027, p = 0.76, n = 6, respectively) (Supplementary Fig. 1c & 1d). Table 1HI titers in patient samples against seasonal IAV (n = 4) and IBV (n = 6). HI, hemagglutination inhibition; IAV, influenza A virus; IBV, influenza B virus; HA, hemagglutinin; Ct value, cycle threshold value; TCID50, 50% tissue culture infectious dose.SampleHA type/lineageCt valueAntibody titerTCID50IAV-18H129.2123.17 × 102IAV-35H321.01922.00 × 105IAV-63H130.9247.96 × 101IAV-82H124.1481.26 × 104IBV-18VIC27.2< 33.17 × 102IBV-40YAM30.1487.96 × 102IBV-45YAM33.2722.52 × 102IBV-50YAM23.71921.26 × 102IBV-72YAM30.0722.52 × 102IBV-75YAM25.5967.96 × 103 HI titers in patient samples against seasonal IAV (n = 4) and IBV (n = 6). HI, hemagglutination inhibition; IAV, influenza A virus; IBV, influenza B virus; HA, hemagglutinin; Ct value, cycle threshold value; TCID50, 50% tissue culture infectious dose. Discussion and conclusion Understanding the relationship between Ct values and the presence of infectious virus provides critical insights not only for virological research, but also for IPC strategies and clinical decision making. In this study, we investigated the correlation between Ct values and the presence and quantity of infectious IAV and IBV in patient nasopharyngeal samples. Our findings reveal a strong inverse correlation between sample Ct value and infectious virus titers for both IAV and IBV. Importantly, the considerable variability observed across samples precludes the establishment of a precise Ct value cut-off above which the probability of a positive virus culture is extremely low, indicating that samples with high Ct values may still contain infectious virus. Conversely, it is also possible that viral RNA persists after infectious virus is no longer detectable. No measurable decline in infectious virus titers was observed in neither the A/NL/602/09 stock, nor the seasonal IAV- and IBV-positive NP samples over the number of cycles tested. These findings suggest that a limited number of freeze-thaw cycles have less effect on (seasonal) influenza viruses than is often assumed. However, the effect of freeze-thaw cycles on virus viability is likely virus- and handling dependent, warranting further research. As we performed quantitative virus culture, rather than relying on the commonly used binary outcome of positive or negative culture, we were able to demonstrate a robust inverse correlation between sample Ct values and infectious virus titers for both seasonal IAV and IBV. This confirmed that lower Ct values strongly correlate with higher viral titers, and vice versa. Some variability in titers was observed for a given Ct value, as Ct values and viral titers do not scale in a strict one-to-one relationship. Such deviations are, however, expected and likely reflect biological variability inherent to clinical samples, including factors such as heterogeneity in host-derived RNA, the presence of non-infectious viral particles, local immune responses, or variations in sample quality. Despite these limitations, our findings support the use of Ct values as a semiquantitative proxy for infectious viral load in patient-derived samples. A calculated probability of obtaining a positive virus culture persists even at high Ct values for both seasonal IAV and IBV. Notably, we could not identify a definitive Ct value threshold beyond which infectious virus could no longer be recovered, indicating that infectious virus may still be present at high Ct levels. While these probabilities are derived from calculations due to practical limitations in obtaining large, evenly distributed sample sized for each specific Ct, they are supported by empirical observations. For example, we successfully cultured IBV from 100 µL of a sample with a Ct value of 39.5 (213 RNA copies mL−1, 21 RNA copies in 100 µL), demonstrating that high Ct values or low RNA concentrations do not categorically rule out the presence of infectious virus. No significant differences in Ct values or virus titers were observed between the H1- and H3 subtypes of seasonal IAV, indicating comparable viral loads and replication efficiencies across these subtypes in clinical samples. However, it cannot be excluded that other zoonotic subtypes, such as the H5 subtype, may exhibit different replication kinetics. Moreover, in contrast to the seasonal IAV subtypes, a significant difference in both Ct values and virus titers was detected between the VIC and YAM sublineages of IBV. These differences may reflect underlying genetic or phenotypic differences that may influence replication competence between IBV sublineages. However, these findings should be interpreted with caution, as our study was not specifically designed or sufficiently powered to investigate the differences between virus sublineages or subtypes. It is also notable that a large portion of IBV samples could not be cultured, likely due to the relatively high median Ct values observed in these samples. Moreover, the unavailability of detailed sample metadata limits our ability to draw any definitive conclusions. Despite the observed differences in Ct values and virus titers between the IBV sublineages, a clear correlation between Ct values and infectious virus titers was observed for both VIC and YAM sublineages, indicating a consistent strong inverse correlation between Ct values and infectious virus titers for both the VIC and the YAM sublineage. Our findings may have direct implications for clinical decision-making and IPC strategies. For instance, in our clinical practice, the initiation of direct-acting antiviral agents (DAAs), which inhibit viral replication, is often debated when high Ct values are observed in samples from hospitalized patients. This hesitation is based on the assumption that high Ct values may indicate an absence of infectious (or replicating) virus, rendering the use of DAAs unnecessary. A similar assumption informs IPC decisions, where isolation measures may be discontinued early, or not implemented at all, for patients with high Ct values. However, as demonstrated in this study, our data challenge this assumption for seasonal IAV and IBV. While we did observe a strong inverse correlation between Ct value and infectious virus titer, our findings also indicate that infectious virus can still be detected even at higher Ct values. This implies that patients with high Ct values may still be shedding infectious virus, albeit at lower levels compared to those with low Ct values. This aspect alone may influence transmissibility and, by extension, IPC measures, as infectious viral load is one of the various proxies of transmission risk23,24. Our findings therefore underscore the importance of not relying solely on Ct values when making decisions regarding antiviral treatment or isolation. Our findings contrast with results for SARS-CoV-2, where, among others, Van Kampen et al.8 and Wölfel et al.9 observed only a 10% probability of a positive SARS-CoV-2 culture at RNA concentrations of approximately 7 − 6 RNA Log10 copies mL−1, while seasonal IAV and IBV showed a 100% probability of positive virus cultures at these RNA levels. It is important to note that the availability and optimization of permissive cell lines may vary between viruses, which can significantly influence culturability outcomes and introduce potential biases. In this study, we used cell lines fully optimized for seasonal IAV and IBV culture. Such optimization may not have been achieved for the culture of SARS-CoV-2, as these studies were conducted during the early stages of the pandemic. Improvements in SARS-CoV-2 culture methodologies over time could potentially have increased culture efficiencies, potentially resulting in efficiencies comparable to those observed for seasonal IAV and IBV in our study. Yet, another study from the same period has reported higher rates of SARS-CoV-2 culturability at higher Ct levels or lower RNA concentrations25. It is, however, difficult to make direct comparisons due to differences in study approaches, such as the clustering of Ct values. This can result in loss resolution near important Ct value thresholds due to averaging effects, which further complicates interpretation. Overall, our observations show greater culturability for seasonal IAV and IBV at higher Ct values compared to SARS-CoV-2. However, as indicated with the example of SARS-CoV-2 above, direct comparisons between different viruses should be interpreted with caution. A strong correlation between patient sample Ct value and RNA concentrations was observed for both seasonal IAV and IBV, although a variability in RNA concentration was observed at any given Ct value. To perform the different PCR assays, two different RNA isolations were required. Initial RNA isolation was performed by the Panther Fusion system, however the extracted RNA is unretrievable once the rRT-PCR analysis was completed. For this reason, RNA had to be re-extracted from the original patient samples for RT-dPCR analysis. In addition, as discussed before, biological variability is inherent to clinical samples. We therefore believe that variances in isolation efficiency between the two different isolation methods in combination with biological variances between clinical samples explain the variance in RNA concentrations per Ct value. Antibody titers ≥ 40 did not affect Ct values or infectious virus titers in this study, indicating that the presence of antibodies against the HA protein do not affect influenza virus culture outcomes. However, as the sample size was limited, no autologous serum samples corresponding to culture negative NP samples were available, and information on influenza virus vaccination history was unavailable, further interpretation of the data is not possible. Despite these constraints, our observations were remarkably different from those reported for SARS-CoV-2, where cultures remained negative once neutralizing antibody concentrations reached 1:808. A notable limitation of this study was the inability to access detailed sample metadata due to legal restrictions under Dutch law. As a result, key variables, such as the interval between symptom onset and sample collection, as well as patient age, were unavailable. Both factors are known to significantly influence viral shedding kinetics26,27 and may have introduced potential confounding effects. In conclusion, this study demonstrates a robust inverse correlation between Ct values and infectious virus titers in patient nasopharyngeal samples. These findings support the use of Ct values as a semiquantitative proxy for infectious viral load in seasonal influenza virus positive-clinical specimens. However, no clear Ct value cut-off could be defined above which there was no probability of obtaining positive seasonal IAV and IBV cultures, highlighting the need for caution when interpreting molecular diagnostic results. This has important implications for both clinical decision-making and the assessment of infectious risk in patients with influenza virus infections. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We thank the Dutch National Influenza Center (NIC, contracted by the Dutch Ministry of Health, Welfare and Sport) for providing NP samples and PCR reagents. We thank Y. Kawaoka (University of Wisconsin-Madison, Wisconsin, USA) for providing hCK cells. We thank D.A.M.C. Van de Vijver (Department of Viroscience - Erasmus Medical Center, Rotterdam, The Netherlands) providing statistical tools. Perplexity AI tool was used to check for spelling, grammar and readability, not for the interpretation of data, or anything else. Author contributions K.S.S., J.J.A.v.K., R.M., R.A.M.F., S.H., and P.L.A.F. conceptualized and designed the study. K.S.S., D.G.J.C.M., T.B., D.d.M., and M.v.G conducted the experiments. K.S.S., J.J.A.v.K., R.M., R.A.M.F., S.H., and P.L.A.F. interpreted the data. P.L.A.F. supervised this project. K.S.S. drafted the manuscript, which was critically reviewed by all other authors. All authors read and approved the final manuscript. Funding This study was funded by the Pandemic and Disaster Preparedness Center (PDPC): reference number 2022.002. Data availability All raw data used to support the findings of this study are available upon request from the corresponding author. Competing interests The authors declare no competing interests. Ethical approval The re-use of residual patient material for research purposes was approved by the regional medical ethics committee “Medisch Ethische Toetsings Commissie (METC)” at Erasmus Medical Center, Rotterdam, The Netherlands under METC-2022-0675. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All raw data used to support the findings of this study are available upon request from the corresponding author.